An online talk from Professor Nicola Curtin, Newcastle University, on the development of anti-cancer agent rucaparib
PARP inhibitors (PARPi) represent a paradigm shift in cancer treatment by exploiting tumour-specific defects rather than trying to overcome tumour biology that promote their growth. Initial approvals of PARPi were for ovarian cancer but now include breast, prostate and pancreatic cancer.
In this talk, Professor Nicola Curtin will describe the development of the PARPi, Rubraca®, as well as the part scientists in Newcastle University played, and the collaborations with scientists in academia and the pharmaceutical industry that enabled Rubraca®'s final development to the approval stage.
It is clear that the success of this development was also dependent on several fortuitous events and coincidences of timing, which will also be touched upon in this talk.
Cost and booking
This event is free to attend and open to all. Advance registration is essential through the link at the top of the page.
For specific event queries, please contact the branch chair, Professor Caroline Austin at firstname.lastname@example.org
For booking or website queries, please contact Harriet McAra at email@example.com
or on 020 3925 3445.